InsiderTrades

Form 4 for ARQT Arcutis Biotherapeutics, Inc.

Accepted 2021-07-06 00:00:00 ET · period of report 2021-07-01 · accession 0001567619-21-013033 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2021-07-06 2021-07-01 ARQT Welgus Howard G. Dir M - OptEx $3.94 +2,200 184.1K +1% +$8,672
DM 2021-07-06 2021-07-01 ARQT Welgus Howard G. Dir S - Sale+OE $26.13 -2,200 181.9K -1% -$57.5K
DM 2021-07-06 2021-07-01 ARQT Welgus Howard G. Dir M - OptEx $0.00 -2,200 23.4K -9% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2021-07-01 M A 781 $1.68 183,068 D — — (F2) Includes 6,750 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.
2 Common Common Stock 2021-07-01 S D 1,950 $26.03 182,146 D — — (F3) The transaction was executed in multiple trades in prices ranging from $25.70 to $26.50, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. (F2) Includes 6,750 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.
3 Common Common Stock 2021-07-01 M A 391 $1.68 182,287 D — — (F2) Includes 6,750 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.
4 Common Common Stock 2021-07-01 S D 250 $26.87 181,896 D — — (F4) The transaction was executed in multiple trades in prices ranging from $26.76 to $27.17, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. (F2) Includes 6,750 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.
5 Common Common Stock 2021-07-01 M A 1,028 $6.52 184,096 D — — (F2) Includes 6,750 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.
6 Derivative Stock Option (Right to Buy) 2021-07-01 M D 391 $0.00 10,933 D $1.68 · — to 2029-03-13 391 Common Stock (F6) The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.
7 Derivative Stock Option (Right to Buy) 2021-07-01 M D 1,028 $0.00 9,862 D $6.52 · — to 2029-11-20 1,028 Common Stock (F7) The option vests monthly over a four year period beginning November 20, 2019, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.
8 Derivative Stock Option (Right to Buy) 2021-07-01 M D 781 $0.00 23,428 D $1.68 · — to 2029-03-13 781 Common Stock (F6) The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.